Slide 1: Topline Results: ADAPT-SC Bridging Study in gMG
Together We Discover Reaching Patients Through Immunology Innovation March 22, 2022 Topline Results: ADAPT - SC Bridging Study in gMG 1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by argenx se (“ argenx ” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter
Slide 3: Generalized Myasthenia Gravis Patient Experience: Living with gMG
GENERALIZED MYASTHENIA GRAVIS Patient Experience 1/2 Despite taking an average of 2.3 current treatments , 61% of patients have poor well - being according to WHO - 5 Index, and reported a mean of residual 8.3 symptoms related to gMG of Patients gMG is characterized by debilitating muscle weakness a
Slide 4: Multiple Formulations Aim to Offer Patients Optionality
4 Multiple Formulations A im to Offer P atients O ptionality 10 mg/kg SC efgartigimod Intravenous infusion Single subcutaneous injection 1000mg
Slide 5: Innovative Trial Designed to Accelerate Path Forward
Leveraged correlation between pharmacodynamic and clinical effect as observed in ADAPT Met primary endpoint, demonstrating noninferior total IgG reduction at day 29 with subcutaneously administered efgartigimod compared to intravenous (IV) administration Secondary endpoints show clinical improvement
Slide 6: ADAPT-SC Bridging Strategy Leverages Correlation Between Pharmacodynamic and Clinical Effect
Efgartigimod - treated patients from Phase 3 ADAPT 6 SC Bridging Strategy Leverages Correlation Between Pharmacodynamic and Clinical Effect 6 • ADAPT established association of total IgG and MG - ADL following efgartigimod treatment • Phase 1 HV data showed SC efgartigimod has similar PD effect as V
Slide 7: ADAPT-SC Bridging Strategy Design
ADAPT - SC Bridging Strategy Design 7 DESIGN 110 adult gMG patients MGFA Class II, III, IV Anti - AChR antibody positive (n=91) and negative (n=19) MG - ADL score ≥5 a On ≥1 stable gMG treatment b 2 weeks screening Patients randomized 1:1 to receive 1000 mg SC efgartigimod or VYVGART All patients re
Slide 8: Primary Endpoint Met: SC Efgartigimod Noninferior to IV
Primary Endpoint Met: SC Efgartigimod Noninferior to IV Mean total IgG reduction from baseline at day 29 AChR - Ab, acetylcholine receptor antibody; MG - ADL, Myasthenia Gravis Activities of Daily Living; MSE, minimal symptom expression Howard JF, et al. Lancet Neurol . 2021;20(7):526 - 536. Primary
Slide 9: Consistent Clinical Efficacy Between SC and IV
SECONDARY QMG responder: ≥3 - point reduction for ≥4 consecutive weeks during the first cycle Consistent Clinical Efficacy Between SC and IV SC efgartigimod VYVGART n =38/55 MINIMAL SYMPTOM EXPRESSION 69.1% 69.1% SECONDARY MG - ADL responder: ≥2 - point reduction ≥4 consecutive weeks during the fi
Slide 10: Fast, Deep and Durable Responses
10 Fast, Deep and Durable Responses T o tal change from baseline in MG - ADL score over time across ADAPT and ADAPT - SC T o tal change from baseline in QMG score over time across ADAPT and ADAPT - SC ADAPT - SC ADAPT - SC Mean MG - ADL reduction Mean QMG reduction
Slide 11: Safety: Summary of Adverse Events
Safety: Summary of Adverse Events SC efgartigimod (n=55) IV efgartigimod (n=55) Number of patients with an Adverse Event (AE) n (%) 37 (67.3) 28 (50.9) Number of patients with an AE grade ≥3 n (%) 9 (16.4) 4 (7.3) Most frequent AEs n (%) Injection site reactions* 21 (38.2) 1 (1.8) Headache 7 (12.7)
Slide 12: Differentiated Treatment Options for gMG Patients
Differentiated Treatment Options for gMG Patients 12 Eri, living with gMG SC efgartigimod s ingle injection ADAPT - NXT Continuous Dosing Future Delivery Vehicles and Formulations (e.g., pre - filled syringe, Elektrofi , autoinjector) 12
Slide 13: SC Formulation Leveraged Across Indications
NEURO HEME SKIN KIDNEY Key: 13 SC Formulation Leveraged Across Indications gMG ITP Pemphigus CIDP BP Myositis Membranous Nephropathy Lupus Nephritis COVID - 19 - mediated POTS Sjogren’s Syndrome FORMULATIONS ACROSS MULTIPLE INDICATIONS, THERAPEUTIC FRANCHISES, AND MOLECULES ENHANZE TM SUBCUTANEOUS F
Slide 14: Where critical patient need meets breakthrough science
Where critical patient need meets breakthrough science That is where we redefine immunology 14
Slide 15: Together We Discover Reaching Patients Through Immunology Innovation
Together We Discover Reaching Patients Through Immunology Innovation 15